Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

NCT01657331 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT01657331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01657331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Lead sponsor
Columbia University
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2012
Completion date
June 30, 2018
Enrollment
65 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, hodgkin lymphoma